Prestige BioPharma Limited (KRX:950210)
South Korea
· Delayed Price · Currency is KRW 12,040
+910 (8.18%)
Last updated: Jun 27, 2025
Prestige BioPharma Cash Flow Statement
Financials in millions KRW. Fiscal year is July - June.
Millions KRW. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2019 |
Net Income | 21,788 | -32,921 | 17,569 | -211,450 | -7,391 | -14,997 | Upgrade
|
Depreciation & Amortization | 16,267 | 16,267 | 11,650 | 3,867 | 1,667 | 1,185 | Upgrade
|
Loss (Gain) From Sale of Assets | -89.4 | -89.4 | -55.17 | -266.37 | 0.36 | - | Upgrade
|
Asset Writedown & Restructuring Costs | - | - | 15,114 | 72,607 | - | - | Upgrade
|
Loss (Gain) From Sale of Investments | - | - | 693.39 | 18,966 | -15,081 | 599.83 | Upgrade
|
Stock-Based Compensation | 52.41 | 52.41 | 1,943 | 3,774 | 2,955 | - | Upgrade
|
Provision & Write-off of Bad Debts | -33.31 | -33.31 | -70,640 | - | - | - | Upgrade
|
Other Operating Activities | -110,251 | -42,356 | -17,826 | 85,640 | 330.51 | 3,816 | Upgrade
|
Change in Accounts Receivable | 674.94 | 674.94 | -1,050 | - | - | 2,021 | Upgrade
|
Change in Inventory | 7,752 | 7,752 | -10,038 | -24,041 | - | - | Upgrade
|
Change in Accounts Payable | 2,459 | 2,459 | -316.4 | 1,641 | - | - | Upgrade
|
Change in Unearned Revenue | -5.21 | -5.21 | -660.52 | 564.62 | 578.1 | -1,674 | Upgrade
|
Change in Other Net Operating Assets | 172.41 | 172.41 | -6,658 | 2,791 | 1,495 | -3,371 | Upgrade
|
Operating Cash Flow | -61,213 | -48,027 | -60,274 | -45,907 | -15,446 | -12,421 | Upgrade
|
Capital Expenditures | -37,753 | -20,063 | -48,363 | -56,429 | -949.11 | -1,340 | Upgrade
|
Sale of Property, Plant & Equipment | 72.87 | 51.21 | 1,133 | 26,428 | - | - | Upgrade
|
Divestitures | - | - | 40,039 | - | - | - | Upgrade
|
Sale (Purchase) of Intangibles | -2,604 | -7,463 | -17,254 | -11,684 | -17,162 | -17,393 | Upgrade
|
Investment in Securities | -30,245 | 159,987 | -133,827 | -25,239 | - | - | Upgrade
|
Other Investing Activities | -1,337 | -46.85 | 9,662 | 12,555 | -2,801 | 694.11 | Upgrade
|
Investing Cash Flow | -71,867 | 132,465 | -148,610 | -184,685 | -20,912 | -18,039 | Upgrade
|
Long-Term Debt Issued | - | - | 55,772 | - | 2,769 | 4,783 | Upgrade
|
Long-Term Debt Repaid | - | -2,771 | -2,589 | -4,504 | -895.88 | -221.95 | Upgrade
|
Net Debt Issued (Repaid) | 51,786 | -2,771 | 53,183 | -4,504 | 1,873 | 4,561 | Upgrade
|
Issuance of Common Stock | - | 1,307 | - | - | 466,094 | - | Upgrade
|
Other Financing Activities | - | - | - | - | -13,450 | 0 | Upgrade
|
Financing Cash Flow | 51,781 | -1,464 | 53,183 | -4,504 | 454,517 | 66,141 | Upgrade
|
Foreign Exchange Rate Adjustments | 1,670 | 608.72 | 6,888 | -3,177 | -277.54 | -72.67 | Upgrade
|
Miscellaneous Cash Flow Adjustments | -0 | -0 | 0 | 0 | 0 | - | Upgrade
|
Net Cash Flow | -79,629 | 83,582 | -148,813 | -238,273 | 417,880 | 35,608 | Upgrade
|
Free Cash Flow | -98,966 | -68,091 | -108,636 | -102,336 | -16,396 | -13,761 | Upgrade
|
Free Cash Flow Margin | -1142.47% | -9881.47% | -67125.45% | - | - | - | Upgrade
|
Free Cash Flow Per Share | -1643.50 | -1133.03 | -1807.71 | -1702.88 | -317.73 | -322.63 | Upgrade
|
Cash Interest Paid | 10,743 | 6,082 | 1,834 | 436.07 | 477.47 | 165.7 | Upgrade
|
Cash Income Tax Paid | - | -179.73 | 796.41 | 591.82 | 34.08 | 98.47 | Upgrade
|
Levered Free Cash Flow | -93,834 | -55,426 | -23,046 | -114,523 | -22,341 | -24,081 | Upgrade
|
Unlevered Free Cash Flow | -89,206 | -50,799 | -22,451 | -114,511 | -22,337 | -24,081 | Upgrade
|
Change in Net Working Capital | 26,272 | 694.59 | -28,875 | -22,642 | -2,642 | -1,525 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.